ProQR Therapeutics N.V
Research ProQR Therapeutics N.V (PRQR) on Bullrun: market cap USD 335.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRQR
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 335.87M
- Financial periodQ1 2026
- RevenueEUR 2.03M
- Net income-EUR 45.49M
- Free cash flow-EUR 49.10M
Valuation Snapshot
latest market cap is USD 335.87M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 15.91M | -EUR 42.18M | -EUR 53.81M | n/a | -0.72 | EUR 92.41M | EUR 15.96M | EUR 49.37M |
| FY2024 | EUR 18.91M | -EUR 27.76M | -EUR 37.81M | n/a | -0.54 | EUR 149.41M | EUR 17.22M | EUR 88.56M |
| FY2023 | n/a | n/a | n/a | n/a | -0.63 | EUR 118.93M | EUR 19.73M | EUR 41.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 335.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 212.83M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 278.81M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 160.69M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 264.31M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 571.04M | n/a | n/a | n/a |
About ProQR Therapeutics N.V
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ProQR Therapeutics N.V's market cap?
ProQR Therapeutics N.V's market capitalization is USD 335.87M.
What does ProQR Therapeutics N.V do?
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases.